Anti-SAMHD1 Antibody

Western Blot Validation in Human Daudi Cell Lines
Loading: 15 μg of lysates per lane. Antibodies: SAMHD1 A00592-1, 1 μg/mL, in (A: the absence and B: the presence of blocking peptide), (1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Overexpression Validation in 293T Transfected Cells
Loading: 15 μg of lysates per lane. Antibodies: SAMHD1 A00592-1 (0.1 μg/mL), (1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. 293 cells were transfected with (1) wild-type SAMHD1 or (2) SAMHD1 (mutation T592A).

Immunohistochemistry Validation of SAMHD1 in Human Brain Tissue
Immunohistochemical analysis of paraffin-embedded Human Brain Tissue using anti- SAMHD1 antibody (A00592-1) at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 ˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Immunofluorescence Validation of SAMHD1 in Human Daudi cells
Immunofluorescent analysis of 4% paraformaldehyde-fixed Human Daudi Cells labeling SAMHD1 with A00592-1 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

KO Validation of SAMHD1 in xenograft mice (Kodigepalli et al., 2018)
THP-1 control and SAMHD1 KO (THP-1/KO) cells were injected into NSG (non-obese diabetic/severe combined immune deficient-gamma) mice. Protein expression levels of SAMHD1 were examined by Western blot with anti-SAMHD1 antibodies (A00592-1) and SAMHD1 was not detected in THP-1/KO cells.

Overexpression Validation of SAMHD1 in CD4+ T-cells from a healthy donor and transformed CD4+ T-cell lines (Kohnken et al., 2017)
MT1, MT2, SLB-1, and C8166 were from leukemia patients and HH, HuT78, and HuT102 were from cutaneous T-cell lymphoma (CTCL) patients. SAMHD1 protein expression detected by anti-SAMHD1 antibodies (A00592-1) was significantly increased in normal CD4+ T-cells as compared to leukemia- and CTCL- derived CD4+ T-cell lines. This blot is representative from four independent experiments with four healthy donors.

Overexpression of SAMHD1 in CD4+ T-cells from Healthy Donors and Sézary Syndrome (SS) patients (Kohnken et al., 2017)
SAMHD1 protein expression detected by anti-SAMHD1 antibodies (A00592-1) was significantly reduced in CD+ T-cells from 15 SS patients as compared to those from 7 healthy donors.

Regulated Expression Validation of SAMHD1 in CD4+ T-cells from a healthy donor (Kohnken et al., 2017)
SAMHD1 protein expression detected by anti-SAMHD1 antibodies (A00592-1) was significantly decreased by about 40% relative to control cells at 48hr post-nucleofection with miR-181b.

Regulated Expression Validation of SAMHD1 in MT2 CD4+ T-cells from leukemia patients (Kohnken et al., 2017)
SAMHD1 protein expression detected by anti-SAMHD1 antibodies (A00592-1) was significantly increased by 5-fold at 48hr post-nucleofection with miR-181family inhibitor treatment.